Combining the experimental Genentech Inc. antibody drug pertuzumab and the breast cancer drug Herceptin with docetaxel chemotherapy translated into metastatic breast cancer patients living more than a half-year longer without the disease progressing, according to results of a trial by the South San Francisco biotech giant.
Patients receiving the three-drug combination, who had received no previous treatment for HER2-positive breast cancer that had spread to other parts of their body, lived a median of 18.5 months without the disease progressing, compared to 12.4 months for patients on only Herceptin and chemo.
No comments:
Post a Comment